The SWOG Statistical and Data Management Center (SDMC) plays a vital role in SWOG's overall mission to direct and participate in clinical trials tht will lead to effective treatment and prevention of cancer and to improve quality of life for cancer patients and survivors. The SDMC provides statistical leadership and data management expertise in the design, implementation, monitoring, analysis and interpretation of clinical trials and translational medicine studies. Key SDMC goals include the following: a) to design and implement statistically rigorous and efficient clinical trials;b) to carefully monitor ongoing trils and use state-of-the-art statistical analysis methods to analyze and interpret study results;c) to conduct statistical methods research in clinical trial design and analysis, and the analysis of translational medicine studies;d) to develop systems and utilize technologies for high quality and timely collection, review, storage and retrieval of clinical and biologic data;e) to educate SWOG investigators and other oncology research professionals in leading edge scientific design, statistical techniques and data management methods;f) to evaluate novel strategies for the efficient collection of specific types of patient data including electronic medical record (EMR and web-based methods;and g) to be a dynamic member of the NCTN by providing a wealth of experience and leadership for NCTN endeavors such as steering committees and working groups. The SWOG SDMC contributes meaningfully to the goals of SWOG within the NCTN to provide generalizable, high quality and efficient strategies that can be used by other clinical trials organizations and researchers in the conduct of oncology clinical trials and analysis of associated biologic studies.
Well designed and conducted clinical trials are the primary means for improving therapy for cancer, advancing the chance for cure and increasing the length and quality of life of patients. The SWOG SDMC aims to be a leader in the field through efficient and high-quality design, management, and analysis of these trials, thereby helping to ensure that the results of clinical trials have the greatest potential impact on cancer patients.
|Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95|
|Papamichael, Demetris; Renfro, Lindsay A; Matthaiou, Christiana et al. (2016) Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. J Geriatr Oncol 7:422-429|
|Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2016) Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer 17:113-8.e1-2|
|Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2016) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv :|
|Hussain, Maha; Tangen, Catherine; Higano, Celestia et al. (2016) Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details. J Clin Oncol 34:280-5|
|Press, Oliver W; Li, Hongli; SchÃ¶der, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7|
|Zhan, Xiang; Girirajan, Santhosh; Zhao, Ni et al. (2016) A novel copy number variants kernel association test with application to autism spectrum disorders studies. Bioinformatics 32:3603-3610|
|Baljevic, Muhamed; Dumitriu, Bogdan; Lee, Ju-Whei et al. (2016) Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. Acta Haematol 136:210-218|
|Puvvada, Soham D; Stiff, Patrick J; Leblanc, Michael et al. (2016) Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Br J Haematol 174:686-91|
|Cheung, Winson Y; Renfro, Lindsay A; Kerr, David et al. (2016) Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. J Clin Oncol 34:1182-9|
Showing the most recent 10 out of 95 publications